A new machine learning technique can predict the dynamics between microbes and therapeutics with unprecedented accuracy.
A*STAR researchers use digital drug simulators to predict the efficacies of repurposed antivirals for treating COVID-19.
Serology testing may be fast and easy to perform, but there are still some limitations that need to be overcome, suggests Laurent Renia.
Antibodies that recognize the SARS-CoV-2 spike protein show potential for diagnosing COVID-19.
The presence of memory T cells in COVID-19-recovered patients hints at their importance in COVID-19 immunity.
Could there be a drug that can both treat and protect against COVID-19? The answer may be found in antibody drugs, a promising therapeutic modality against the coronavirus.
A new test manufactured by A*STAR’s Diagnostics Development Hub in partnership with Duke-NUS Medical School could reveal if an individual is likely immune to COVID-19.
Sebastian Maurer-Stroh shares how bioinformatics has enabled Singapore to respond quickly to COVID-19 and will continue to play an important role in ongoing surveillance.
Two coronavirus experts suggest that the best way to control an outbreak may be to first understand viral biology and behavior in animals and humans.
Surveillance and contact tracing are key to limiting the widespread transmission of COVID-19 in the community, experts find.
Scientists at A*STAR have found that a mutation in SARS-CoV-2 called ∆382 leads to milder clinical outcomes, with implications for COVID-19 treatments and vaccines.